VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Update

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 1,791,894 shares, a growth of 40.6% from the November 30th total of 1,274,319 shares. Based on an average daily volume of 992,442 shares, the days-to-cover ratio is currently 1.8 days. Approximately 4.7% of the company’s shares are sold short. Approximately 4.7% of the company’s shares are sold short. Based on an average daily volume of 992,442 shares, the days-to-cover ratio is currently 1.8 days.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of VTGN. ADAR1 Capital Management LLC increased its holdings in VistaGen Therapeutics by 246.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company’s stock worth $1,052,000 after buying an additional 299,304 shares during the period. AdvisorShares Investments LLC increased its stake in shares of VistaGen Therapeutics by 27.7% in the second quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company’s stock worth $406,000 after acquiring an additional 44,000 shares during the period. GSA Capital Partners LLP acquired a new stake in shares of VistaGen Therapeutics in the third quarter worth $112,000. Millennium Management LLC purchased a new position in shares of VistaGen Therapeutics during the third quarter worth $73,000. Finally, Bank of America Corp DE lifted its position in VistaGen Therapeutics by 926.0% during the third quarter. Bank of America Corp DE now owns 34,657 shares of the company’s stock valued at $123,000 after purchasing an additional 31,279 shares during the period. 78.39% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently weighed in on VTGN. Maxim Group reiterated a “hold” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Jefferies Financial Group reiterated a “hold” rating and set a $0.90 target price (down from $15.00) on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. William Blair reissued a “market perform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Stifel Nicolaus downgraded shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price target on the stock. in a research note on Wednesday, December 17th. Finally, Wall Street Zen lowered shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $0.95.

VistaGen Therapeutics Trading Down 9.4%

Shares of VTGN stock opened at $0.66 on Tuesday. VistaGen Therapeutics has a 12-month low of $0.65 and a 12-month high of $5.14. The business’s fifty day simple moving average is $3.60 and its 200-day simple moving average is $3.22. The company has a market cap of $26.06 million, a PE ratio of -0.35 and a beta of 0.56.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Thursday, November 13th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The company had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.16 million. On average, equities analysts forecast that VistaGen Therapeutics will post -1.77 earnings per share for the current year.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.